"This is the first clinical trial to demonstrate that semaglutide may improve liver fibrosis in patients with advanced MASH, including those with compensated cirrhosis," said Rohit Loomba, MD, senior author of the study, gastroenterologist and hepatologist at UC San Diego Health and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine
Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, et al
As patients lose weight on GLP-1 therapy, increased mobility often becomes feasible, creating opportunities for enhanced physical activity that further supports weight management and joint function
From a litigation standpoint, the argument is clear: patients were never given the chance to make an informed decision, and many never would have agreed to use Ozempic had they been properly warned
The 2026 Regulatory Landscape The legal foundation for compounded GLP-1 medications shifted in early 2026